GoodRx Holdings, Inc. Class A GDRX 深 沪
等待开盘 05-16 09:30:00 美东时间
2.43
-0.060
-2.41%
华盛通- 最 高2.52
- 今 开2.47
- 成交量 138.23万股
- 最 低 2.42
- 昨 收 2.49
- 总市值 8.23亿
- 52周最高 5.8099
- 市盈率 静 28.49
- 换手率 0.41%
- 52周最低 1.77
- 委 比 -60.79%
- 总股本 3.39亿
- 历史最高 64.219
- 量 比 0.74
- 振 幅 4.02%
- 历史最低 1.77
- 每 手 1
- 风险率 0.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Why Jim Cramer Says 'Pull The Trigger' On Chevron
Cramer recommends buying Chevron (CVX) due to good cash flow and limited downside, and waiting to buy Vertiv (VRT) on a decline. GoodRx (GDRX) reports mixed earnings, Sterling Infrastructure (STRL) can't be bought now after a 52% increase.
05-13 19:52
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
TD Cowen Maintains Buy on GoodRx Holdings, Raises Price Target to $4
TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $3 to $4.
05-12 02:24
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
GoodRx Holdings Raises FY2026 Sales Guidance from $750.000M-$780.000M to $765.000M-$785.000M vs $764.443M Est
GoodRx Holdings (NASDAQ:GDRX) raises FY2026 sales outlook from $750.000 million-$780.000 million to $765.000 million-$785.000 million vs $764.443 million estimate.
05-07 04:47
GoodRx Holdings Q1 Adj. EPS $0.07, Inline, Sales $194.006M Beat $185.137M Estimate
GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.07 per share which met the analyst consensus estimate. This is a 22.22 percent decrease over earnings of $0.09 per share from the same period last year.
05-07 04:47
GoodRx Providing Access To Novo Nordisk's Ozempic Pill At $149/Month
GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced that it is providing access to self-pay pricing for Novo Nordisk's Ozempic® pill (oral semaglutide), helping eligible
05-01 20:14
GoodRx Names Thomas Chan Chief Accounting Officer
GoodRx Holdings ( ($GDRX) ) just unveiled an announcement. GoodRx Holdings, Inc...
04-25 04:48
GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market
GoodRx shares rise as Wegovy HD rollout expands self-pay access, with tiered pricing and mixed technical signals.
04-16 01:25
